KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Minority Interest (2017 - 2020)

Ionis Pharmaceuticals has reported Minority Interest over the past 5 years, most recently at $223.2 million for Q3 2020.

  • Quarterly results put Minority Interest at $223.2 million for Q3 2020, up 38.08% from a year ago — trailing twelve months through Sep 2020 was $223.2 million (up 38.08% YoY), and the annual figure for FY2019 was $213.5 million, up 53.47%.
  • Minority Interest for Q3 2020 was $223.2 million at Ionis Pharmaceuticals, up from $217.6 million in the prior quarter.
  • Over the last five years, Minority Interest for IONS hit a ceiling of $223.2 million in Q3 2020 and a floor of $84.3 million in Q4 2017.
  • Median Minority Interest over the past 4 years was $161.7 million (2019), compared with a mean of $157.2 million.
  • Biggest five-year swings in Minority Interest: soared 109.74% in 2019 and later grew 15.87% in 2020.
  • Ionis Pharmaceuticals' Minority Interest stood at $84.3 million in 2017, then skyrocketed by 65.05% to $139.1 million in 2018, then soared by 53.47% to $213.5 million in 2019, then rose by 4.58% to $223.2 million in 2020.
  • The last three reported values for Minority Interest were $223.2 million (Q3 2020), $217.6 million (Q2 2020), and $210.2 million (Q1 2020) per Business Quant data.